Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01283373 (Clinical Trial / Vandortuzumab Vedotin / DSTP3086S)

Study Title
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT01283373)

Trial Description
This is a Phase I, multicenter, open-label, dose-escalation study of DSTP3086S, also known as vandortuzumab vedotin, administered as a single agent by intravenous (IV) infusion to patients with metastatic Castration-Resistant Prostate Cancer (mCRPC).

This trial is sponsored by Genentech. [1]

Study Data

  • Condition: Prostate Cancer
  • Interventions:
  • Phase: I
  • Estimated Enrollment: 87
  • Start: March 2011
  • Estimated Completion: June 2016
  • Last verified: May 2015

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 14, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar